All deals
You are viewing a shared deal. With a free account you access the full showcase and talk directly with whoever manages the deal.
Pre-IPO

Neuralink

Brain-computer interface company implanting devices in human trial participants.

Last published price (USD)$287.71
25 Aug 2026 — 3 Nov 2026+19.9%
25 Aug 202628 Oct 20263 Nov 2026
$287.71Last published price (USD)
$9.62BPost-money valuation
LimitedMarket activity
LiveStatus

Who they are & what they do

SectorHealthcare
Industries
Medical DevicesBrain-Computer InterfacesNeurotechnology
Company overview

Neuralink, co-founded by Elon Musk, develops implantable brain-computer interfaces enabling people with paralysis to control devices by thought, currently in human trials.

Key investors

Ark InvestFounders FundSequoia CapitalThrive CapitalLightspeedQatar Investment AuthorityVy Capital
Founded 2016
Country United States
Website neuralink.com

Website: neuralink.com

Why look at this deal

Highlights

  1. 01BCI Leader
  2. 02Human Trials
  3. 03Medtech Frontier
  4. 04Musk Ecosystem
  5. 05Long Horizon

Deal snapshot

Market activityLimited
Last published price (USD)$287.71
Last roundSeries E
Round dateJune 2025
Amount raised (last round)$650M
Post-money valuation$9.62B
Total funding$1.34B
LFR price/share$50.50

Pre-IPO investment risks

Standard notice applying to all pre-IPO deals. This platform only publishes information about the opportunity: each deal is managed by a regulated, licensed investment firm or bank in the relevant jurisdictions.

  1. Illiquidity. There is no regulated market: the ability to sell depends on secondary-market demand.
  2. Price not guaranteed. The last published price is not an official market price and can vary between transactions.
  3. Uncertain valuation. Based on private rounds and limited transactions, not on audited public financial statements.
  4. No IPO guarantee. The listing may be delayed or never happen; the liquidity horizon is undetermined.
  5. Lock-up. If the company lists, selling restrictions of 90–180 days or longer may apply.
  6. Limited information. Private companies have reduced disclosure obligations and not-always-audited data.
  7. Dilution. Subsequent rounds can dilute existing positions, even significantly.
  8. Transfer restrictions. Rights of first refusal (ROFR) and corporate consents can delay or prevent settlement.

Data room

Public files are open to everyone. The rest unlock once you qualify.

For companies and advisors

Have a deal to bring to market?

Publish your deal on UCapital Dealflow and reach qualified buyers and investors. Data room, NDA and lead management included.

Disclaimer

UCapital Asset Management LLP is authorised and regulated by the Financial Conduct Authority (FCA) in the United Kingdom and by CONSOB in Italy, and operates in the United States through FINRA-licensed US partners and affiliates.

This platform serves informational and technological purposes only: it executes no market transactions, does not constitute a solicitation to invest and provides no financial advice of any kind. The platform lets users manage a deal through the technological tools made available to them, such as the CRM for lead tracking and analytics. No capital raising and no sale is executed on or through the platform: each individual deal is executed offline by the designated regulated entities, in accordance with the regulations in force in each country, their compliance frameworks and under their full responsibility.

The content is intended exclusively for eligible counterparties, professional investors and professional clients as defined by applicable regulations, and does not constitute a public offer. The information is not directed at persons in jurisdictions where its distribution or use would be contrary to local laws or regulations.

The data shown on these pages is public data or data collected and processed by UCapital. For user-created deals, the data is entered by the users themselves, who take full responsibility for what is published: the publication of a deal on the platform does not constitute a recommendation, endorsement or verification by UCapital.

The data shown may not always be real-time and may differ from what is verified in due diligence when contacting the regulated entities responsible for managing the deal. Any prices, valuations and projections are purely indicative.

Every investment carries risks, including the total loss of the capital invested. Past performance is not indicative of future results. Before any decision, investors must carry out their own assessments and consult the regulated entities managing the deal and, where appropriate, their own legal, tax and financial advisers.